Citation Tools

Download PDFPDF

Extended report
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate
Free

Download to a citation manager

Cite this article as:
Genovese MC, Lee E, Satterwhite J, et al
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate